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ABSTRACT
Objective: The objective of this selective evidence based medicine review is to determine
whether or not transdermal glyceryl trinitrate is a safe and effective treatment for primary
dysmenorrhea.
Study Design: Review of two English language randomized control trials (RCTs) published in
1996 and 1999 and one English language pilot study in 1997.
Data Sources: Two double-blind, randomized, placebo-controlled cross-over studies and one
pilot study comparing transdermal glyceryl trinitrate to placebo were found using PubMed,
Medline and OVID.
Outcome Measured: Outcomes measured were based on pain intensity scores (PID) assessed on
a visual analog scale and the time-weighted sum of pain intensity differences (SPID) in the Ali et
al and Moya et al studies. Ali et al converted the SPID into percentages of pain relief, while
Moya et al analyzed the PID and SPID using an analysis of varience (ANOVA) model. Pittrof et
al used a visual analogue self-assessment form to evaluate efficiency, and results were reported
as mean scores.
Results: Pain relief from primary dysmenorrhea was considerably improved with glyceryl
trinitrate therapy as seen in the randomized control trial by Moya et al. The remaining two
studies in this systematic review were limited by study design and didn’t provide a definitive
answer. The pilot study conducted by Ali et al failed to provide clinical significance because
there was no control group for comparison, participants weren’t blinded and two different doses
of the intervention were used at random. Pitroff et al did show improvement in patient
symptoms, but had more than 20% of the participants lost to follow-up. The most common
adverse effect of glyceryl trinitrate therapy was headache when compared to placebo.
Conclusion: The results of this selective EBM review are inconclusive, however do suggest that
glyceryl trinitate may be a safe and effective treatment for primary dysmenorrhea. Due to
limitations within these studies, this topic does warrant additional research.
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INTRODUCTION
Primary dysmenorrhea is defined as lower abdominal pain in women with normal pelvic
anatomy that interferes with daily activities5 and occurs at the beginning of menses. It is
described as cramping, wave-like pain that may radiate to the back and gradually decreases over
the next 12-72 hours after onset4. In addition to the abdominal pain, women can experience
nausea, diarrhea, fatigue and headaches8. There is no current cure for primary dysmenorrhea,
however there are many drugs that are generally helpful for symptom reduction. This paper
evaluates two double blind, randomized cross-over control trials and one pilot study comparing
the efficacy of glyceryl trinitrate as a transdermal medication for primary dysmenorrhea relief.
Dysmenorrhea is one of the most commonly reported menstrual disorder worldwide2 and
is the leading cause of lost time from school and work among women in their teens and
twenties9. The understanding of primary dysmenorrhea is important to the physician assistant
and fellow physician in order to provide the best point of care to patients, as well as to focus on
decreasing morbidity and increasing quality of life for those women who are suffering. In the
United States, the annual economic loss has been estimated at 600 million work hours and 2
billion dollars9. Although an exact number of healthcare visits associated with primary
dysmenorrhea is unknown, it’s estimated that 60-93% of women who menstruate complain of
pain for 1-2 days/month2,8.
The etiology of primary dysmenorrhea is not exactly understood, however it’s thought to
be caused by the release of prostaglandins from the endometrium at the time of menstruation8.
The pain is produced as a result of uterine vasoconstriction, anoxia and sustained contractions3.
Currently the recommended treatment for dysmenorrhea is pain relievers, such as NSAIDs, or
hormonal medications, such as birth control pills in conjunction with heat2. In addition, some

lifestyle changes may be indicated, such as exercise, getting adequate sleep and relaxation
techniques3. Transdermal glyceryl trinitrate may provide a superior alternative for the relief of
primary dysmenorrhea by providing localized relaxation of myometrium contractions.
OBJECTIVE
The objective of this systematic evidence based medicine review is to determine whether
or not transdermal glyceryl trinitrate is a safe and effective treatment for primary dysmenorrhea.
METHODS
Specific selection criteria of two randomized control trials and one pilot study were used
for this review. The population of interest included adolescent females and adult women who
complained of persistent primary dysmenorrhea. The interventions utilized in each study were
transdermal patches, each delivering glyceryl trinitrate at a dose of 0.1 mg/h, 0.2 mg/h or 10
mg/24 hours1,6,7. Comparisons were made between the experimental group receiving transdermal
glyceryl trinitrate patches to the control group who received a visually matched placebo patch.
Outcomes in each study were based on patient oriented evidence that matters (POEMs) and
measurements of the efficacy and tolerability of transdermal glyceryl trinitrate for the treatment
of primary dysmenorrhea.
Key words used in the searches were “transdermal glyceryl trinitrate” and “primary
dysmenorrhea”. All articles searched were published in peer-review journals and in the English
language. The author researched the studies through PubMed, Medline and OVID. Articles were
chosen based on the application to the research practicum and if the outcomes measured POEMs.
Inclusion criteria consisted of primary research studies that were published in 1996 or later with
participates over the age of 12 years old. Exclusion criteria included articles with disease
oriented evidence (DOE), published before 1996, with participants under the age of 12 years old

or patients who experienced painful menses for reasons other than primary dysmenorrhea. The
statistics used in the studies were ANOVA model6, PID, SPID, RRR, ARR, NNT, and p-values.
OUTCOMES MEASURED
Outcomes measured were based on pain intensity scores (PID) assessed on a visual
analog scale and the time-weighted sum of pain intensity differences (SPID) in the Ali et al and
Moya et al studies. Ali et al converted the SPID into percentages of pain relief, while Moya et al
analyzed the PID and SPID using an analysis of variance (ANOVA) model. Pittrof et al used a
visual analogue self-assessment form to evaluate efficiency, and results were reported as mean
scores with 95% confidence intervals. Overall assessment of efficacy and the incidence of
adverse events were analyzed by the Stuart-Maxwell or the McNemar test as appropriate in the
Moya et al study. Safety and tolerability of transdermal glyceryl trinitrate were both measured on
actual reports of patients in the studies.
RESULTS
The demographics of the studies included in this review are outlined in Table 1. One of
the studies was conducted for two consecutive menstrual cycles (Pittrof et al) and two of the
studies were conducted for three consecutive menstrual cycles (Ali et al, Moya et al). All
participants were females who suffer from primary dysmenorrhea. The results were presented in
dichotomous form for studies conducted by Moya et al and Pittrof et al, while results for Ali et al
were reported in a continuous form.
Table 1: Demographics & Characteristics of included studies
Study Type
#
Age
Inclusion
Exclusion
Pts (yrs)
Criteria
Criteria
Ali,
Pilot study
65 18-33
Moderate to
History of
1
1997
severe pain
severe
associated
bleeding
with menses
during
menses,

W/D

Interventions

0

Transdermal
nitroglycerine
0.2mg/hr or
0.1 mg/hr

Moya,
19996

Multi-national,
double blind,
randomized,
crossover
Pittrof, Double blind,
19967 randomized,
placebo
controlled, two
period
crossover

88

Mean=
22.6

Primary
dysmenorrhea

14

17-36,
mean
=27

Persistent and
regular severe
dysmenorrhea
which
interfered
with social
and
professional
lives

concomitant
genitourinary
infections,
concomitant
neoplasia or
history of
arterial
hypotension
Secondary
dysmenorrhea
Evidence of
gynecological
pathology via
transvaginal
ultrasound

14

3

Transdermal
glyceryl
trinitrate
0.1 mg/h
Transdermal
glyceryl
trinitrate
2.5 mg/24 hrs

Ali et al conducted a pilot study that involved 65 women with primary dysmenorrhea
over the course of three consecutive menstrual cycles. This study did not have a control group;
instead all participants used a form of the active medicated patch. The participants were not
blinded to the intervention. The participants were instructed to use transdermal nitroglycerine
patches that delivered either 0.2 mg/h (“Minitran”) or 0.1 mg/h with the onset of primary
dysmenorrhea1. If the pain persisted for 4 hours after the first patch, patients were instructed to
apply a second patch. Eight patients used a patch that delivered 0.2 mg/h of transdermal
nitroglycerine, while the remaining 57 used patches that delivered 0.1mg/h. It is unknown if the
assignment of patients to treatment was randomized or not. Patches were to be applied as
necessary for pain for days 1-3 of the women’s cycles. Pain intensity was measured by the
patients at baseline and then again at 0.5, 1, 2, and 4 hours after patch application. The pain scale
used was: 3 (severe), 2 (moderate) 1 (mild) and 0 (no pain)1. The pain intensity differences

versus baseline values were calculated and the sum of pain intensity differences (SPIDs) were
then converted into percentages of pain relief. Pain relief was defined into three categories:
excellent, satisfactory and unsatisfactory (Table 2).
Table 2: Relief of pain associated with primary dysmenorrhea in patients treated with
transdermal nitroglycerin1
Pain relief
% Pain relief % of Patients
Excellent
>75
47
Satisfactory

40-74

Unsatisfactory <39

43
10

In order to evaluate the data as dichotomous, it was necessary to define a dichotomous
“cut-off.” Since this research practicum is evaluating the use of transdermal nitroglycerin as a
safe and effective pain reliever, the cut-off was defined at satisfactory. Thus, the unsatisfactory
group represents the control event rate (CER), while the satisfactory and excellent groups
represent the experimental event rate (EER). The CER was calculated to be 7% and the EER was
59% (Table 5). The relative benefit increase (RBI) was calculated to be 742% and the absolute
benefit increase (ABI) was 52%. The number needed to treat (NNT) was calculated as 2 (Table
5), meaning 2 people need to be treated with transdermal nitroglycerin in order to prevent one
person from experiencing menstrual pain from primary dysmenorrhea.
The only clinically significant side effect reported was a headache, which was reported
by 20% of the patients1. All of these patients used a second patch due to continued pain after 4
hours of the first patch application.
In the study conducted by Moya et al 88 healthy volunteers participated6. Patients were
evaluated during three menstrual cycles. During two of the cycles the patients were receiving the
transdermal glyceryl trinitrate 0.1 mg/h active medicated patch (“Minitran-F patch”), while the

remaining cycle the patients were receiving a visually matched placebo patch. Patients were
blinded as to which patch they were using. The women were instructed to place the patch on the
lower abdomen on days 1-3 of their menstrual cycles. Each patient ranked her own pain intensity
on a 0-100 visual analog scale, ‘0’ meaning no pain and ‘100’ meaning severe pain. These
observations were recorded at 0.5, 1, 2, 4 and 6 hours after patch application. The study enrolled
88 participants but not all participants were represented in the efficacy results (N=74)6. There
was no mention in either the methods or results section that addressed any participants who
dropped out. Table 3 provides the difference in pain intensity (PID) by hour after patch
application and the sum of the pain intensity difference (SPID). This data is statistically
significant, with a p-value of <0.01.
Table 3: Differences in SPID in those who received Trandsermal glyceryl trinitrate vs. Placebo6
N=74
Pain before patch application
Differences in pain intensity
by hour after patch application
0.5 hour
1 hour
2 hours
4 hours
6 hours
SPID

Trandsermal glyceryl trinitrate Patch Placebo Patch
76.01
75.6
12.0
22.8
32.4
37.2
40.3
186.3

8.0
15.1
20.1
24.4
28.3
122.6

The CER was calculated to be 43% and the EER was 85%. The relative benefit increase (RBI)
was calculated to be 98% and the absolute benefit increase (ABI) was 42%. The numbers needed
to treat was calculated as 3 (Table 5), meaning a physician assistant would have to treat 3 people
with transdermal nitroglycerin in order to attain one beneficial outcome for treatment of
menstrual pain from primary dysmenorrhea.

Additionally, patients proved to use analgesic medication less during the active drug
treatment (20.3%) than during the placebo group (39.2%), with a p-value of being statistically
significant at p<0.051.
The most common adverse event was a headache. Out of the 74 patients who
participated, 26% reported a headache while on the active patch, compared to 6% reported the
same symptom during the one placebo cycle (p<0.001)6 Table 4.
Table 4: Harms from headache of those treated with 0.1 mg/h of transdermal glyceryl trinitrate
compared to a visually matched placebo6
CER
EER
RRI
ARI
NNH
P-value
6%

26%

333%

20%

5

<0.01

The numbers needed to harm was calculated as 5, meaning 5 patients have to be treated
with glyceryl trinitrate to prevent one additional bad outcome, like a headache.
In the Pittrof et al study, one participant was lost to follow up, one withdrew due to
presumed side effects and one did not complete her self-assessment form7. The remaining eleven
women (78.5%) participated in a randomized, double-blind placebo controlled, two period
crossover trail for two consecutive menstrual cycles. The women were provided with adhesive
patches that were either placebo or released 10 mg of glyceryl trinitrate transdermally over 24
hours. The women were instructed to apply one-quarter (2.5 mg) of the patch to their lower
abdomen when menstrual pain began7. The participants recorded their symptoms on a visual
analog self-assessment form. The data was collected and recorded as mean scores for the
outcome measured as a total pain score and as a pain score on the worst day. No statistical
significance was found with the total pain score (p=0.059)7; however, there was statistical
significance found with the improvement of pain scores on the worst day (p=0.048) with a 95%

CI7. The score on the worst day was lower with active treatment than with placebo. The
reduction in the active group was 10.2% of the maximum possible score, while in the placebo
group it was 11.6%. The relative benefit increase (RBI) was calculated to be 7%, while the
absolute benefit increase (ABI) was 4% (Table 5). The number needed to treat was 25 people,
meaning 25 people need to be treated with transdermal glyceryl trinitrate in order to prevent one
person from experiencing menstrual pain from primary dysmenorrhea.
Table 5: Comparison of Dichotomous Data (in percentages)
CER

EER

RBI

ABI

NNT

Ali et al

7%

59%

742%

52%

2

Treatment effect
precision value
Not provided

Moya et al

43%

85%

98%

42%

3

p <0.01

Pittrof et al

56%

60%

7%

4%

25

95% CI

DISCUSSION
This systematic review investigated three primary studies, two of which were randomized
control trials, for the safety and effectiveness of transdermal glyceryl trinitrate as a treatment for
primary dysmenorrhea. The study by Moya et al demonstrated this drug as a safe and effective
treatment. However, the outcome strength of the study conducted by Ali et al did not reach any
statistical significance due to the lack of validity. This study did not randomize or blind the
participants. In addition, the study didn’t provide a p-value or confidence interval. Finally,
although the ABI is 52%, the RBI of 742% indicates that a relative change caused a large over
estimation of benefit. The Pittrof et al provided statistical significance (CI of 95%) that
transdermal glyceryl trinitrates is safe and effective for primary dysmenorrhea, however, the
study only involved 11 participants. More than 20% of participants were not accounted for at the
conclusion of the study, resulting in a wider confidence interval.

Primary dysmenorrhea can affect the quality of life of females who suffer from this
condition and can lead to lost time at school or work, so treatment to improve the lives of these
women is imperative9. The thought that exogenous nitroglycerin could relieve the pain
associated with uterine myometrial contractions is further supported by current use of
nitroglycerin for angina. Nitroglycerin patches have been FDA approved for the prevention of
episodic angina in patients who suffer from coronary artery disease. Exogenous nitrogen causes
vasodilation, which decreases pain. The most common adverse event is a headache. Hypotension
and syncope occur infrequently.
CONCLUSION
There were various limitations to the studies included in this systematic review, thus the
evidence as to whether transdermal glyceryl trinitrate as a safe and effective treatment for
improving the quality of life for patients with primary dysmenorrhea is inconclusive. The pilot
study (by Ali et al) lacked clinical significance because the patients weren’t blinded and there
was no control group. In addition, two doses of glyceryl trinitrate were used, however, the results
were interrupted as one in the same. As mentioned in this study, there is currently a randomized,
double-blind, placebo-controlled study underway to confirm the pilot study results. The results of
this ongoing study may provide more of a definitive clinical answer. Pittrof et al conducted a
well designed study, however, more than 20% of the participants were lost to follow-up.
Similarly, Moya et al provided valid data but lost validity when only 74 out of 88 participates
were account for at the end of the study. In order to authenticate the benefits of transdermal
glyceryl trinitrate as a safe and effective treatment for primary dysmenorrhea, future study is
warranted. In addition, perhaps future research could address lowering the adverse side effect of
headaches associated with the intervention.
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